Physician profile
Daniel Sosh
NPI 1366023723
$3,250.16
in general payments reported to CMS, 2019-2025
16 companies · $1,585 in 2025
The $1,585 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $264 · 2024: $1,276 · 2025: $1,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,125.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $803.02 | 2022-2024 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $397.22 | 2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $324.23 | 2024-2025 | Zoryve |
| Organon LLC | $243.57 | 2025 | Vtama |
| Genzyme Corporation | $229.90 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $225.22 | 2025 | |
| Incyte Corporation | $215.33 | 2024 | Opzelura |
| Janssen Scientific Affairs, LLC | $199.42 | 2024-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $155.51 | 2024 | Sotyktu |
| Galderma Laboratories, L.P. | $118.74 | 2025 | Nemluvio |
| Krystal Biotech INC | $105.97 | 2024 | Vyjuvek |
| Pfizer INC. | $74.40 | 2025 | |
| Biofrontera INC. | $62.12 | 2025 | Ameluz |
| Chiesi USA, INC. | $51.31 | 2025 | Filsuvez |
| Dermavant Sciences, INC. | $24.80 | 2023 | Vtama |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $19.40 | 2023 | Saphnelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.